MedTrace Logo

Prognostic Model of GC/CTX in the Treatment of MN

NCT05667883 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-03-17

No results posted yet for this study

Summary

The goal of this observational study is to explore the factors that can predict the prognosis difference in patients with idiopathic membranous nephropathy (IMN) under the treatment of glucocorticoid + cytoxan. The main questions it aims to answer are:

* to explore the factors that can predict the prognosis difference in patients with IMN under the treatment of glucocorticoid + cytoxan
* to establish a clinical prediction model and verify it to provide a reference for the early Participants will receive standard glucocorticoid + cytoxan treatment and will then be divided into remission and non remission groups based on the treatment effect after the standard treatment cycle. Blood, urine, and fecal samples were collected from patients to explore possible factors influencing treatment efficacy.

Researchers will compare \[remission group and non-remission group\] to see if the gut microbiota and its metabolites are factors that influence the efficacy of treatment.

Conditions

  • Idiopathic Membranous Nephropathy

Interventions

DRUG

glucocorticoid + cytoxan

The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.

Sponsors & Collaborators

  • Qianfoshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2023-07-31
Completion
2023-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05667883 on ClinicalTrials.gov